The remarkable global development of disease-modifying therapies(DMTs) specific for multiple sclerosis(MS) has signifi cantly reduced the frequency of relapse,slowed the progression of disability,and improved the quality of life in patients with MS. With increasing numbers of approved DMTs,neurologists in North America and Europe are able to present multiple treatment options to their patients to achieve a better therapeutic outcome,and in many cases,no evidence of disease activity. MS patients have improved accessibility to various DMTs at no or minimal out-of-pocket cost. The ethical guidelines defi ned by the Edinburgh revision of the Declaration of Helsinki strongly discourage the use of placebo control groups in modern MS clinical trials. The use of an active comparator control group increases the number of participants in each group that is essential to achieve statistical signifi cance,thus further increasing the diffi culty of completing randomized controlled trials(RCTs) for the development of new MS therapies. There is evidence of a high prevalence of MS and a large number of patients in Asia. The belief of the existence of Asian types of MS that are distinct from Western types,and regulatory policies are among the reasons why DMTs are limited in most Asian countries. Lack of access to approved DMTs provides a good opportunity for clinical trials that are designed for the development of new MS therapies. Recently,data from RCTs have demonstrated excellent recruitment of participants and the completion of multi-nation and single-nation MS trials within this region. Recent studies using the Mc Donald MS diagnostic criteria carefully excluded patients with neuromyelitis optica(NMO) and NMO spectrum disorder,and demonstrated that patients with MS in Asia have clinical characteristics and treatment responses similar to those in Western countries. The remarkable global development of disease-modifying therapies (DMTs) specific for multiple sclerosis (MS) has signifi cantly reduced the frequency of relapse, slowed the progression of disability, and improved the quality of life in patients with MS. With increasing numbers of approved DMTs, neurologists in North America and Europe are able to present multiple treatment options to their patients to achieve a better therapeutic outcome, and in many cases, no evidence of disease activity. MS patients have improved accessibility to various DMTs at no or minimal out- of-pocket cost. The ethical guidelines defi ned by the Edinburgh revision of the Declaration of Helsinki strongly discourage the use of placebo control groups in modern MS clinical trials. The use of an active comparator control group increases the number of participants in each group that is essential to achieve statistical signifi cance, thereby further increasing the diffi culty of completing randomized controlled trials (RCTs) for t There is evidence of a high prevalence of MS and a large number of patients in Asia. The belief of the existence of Asian types of MS that are distinct from Western types, and regulatory policies are among the reasons why DMTs are limited in most Asian countries. Lack of access to approved DMTs provides a good opportunity for clinical trials that are designed for the development of new MS therapies. Recently, data from RCTs have demonstrated excellent recruitment of participants and the completion of multi-nation and single-nation MS trials within this region. Recent studies using the Mc Donald MS diagnostic criteria carefully excluded patients with neuromyelitis optica (NMO) and NMO spectrum disorder, and demonstrated that patients with MS in Asia have clinical characteristics and treatment factors similar to those in Western countries.